YAbS







Motavizumab Terminated Naked monospecific

Antibody Information

Entry ID 2281
INN Motavizumab
Status Terminated
Drug code(s) MEDI524
Brand name Numax
mAb sequence source mAb humanized
General Molecular Category Naked monospecific
Format, general category Full length Ab
Format details None
Isotype (Fc) IgG1
Light chain isotype kappa
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) RSV (F glycoprotein)
Indications of clinical studies Prevention of RSV infection in high risk infants
Primary therapeutic area Infectious diseases

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Terminated at regulatory review
Status Inactive
Start of clinical phase (IND filing or first Phase 1) January 15, 2000
Start of Phase 2
Start of Phase 3 October 15, 2004
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company AstraZeneca
Licensee/Partner None
Comments about company or candidate None
Full address of company Cambridge, United Kingdom
Europe
United Kingdom
https://www.astrazeneca.com/our-company/contact-us.html

Description/comment

Motavizumab, an affinity-optimized version of palivizumab, was developed to improve protection against RSV. These antibodies bind RSV F protein, which plays a role in virus attachment and mediates fusion. Described in J Virol. 2010 Aug;84(16):8132-40. doi: 10.1128/JVI.02699-09.

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None